MAAT PHARMA S.A. EO-1
MaaT Pharma SA, a late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival. Its products pipeline includes MaaT013, that is in pivotal phase 3 clinical trial for the treatment of acute graft versus host diseases with gastrointestinal involvement; MaaT033, which is in phase 2b clinical trial for the improve… Read more
Market Cap & Net Worth: MAAT PHARMA S.A. EO-1 (4RD)
MAAT PHARMA S.A. EO-1 (F:4RD) has a market capitalization of $134.74 Million (€131.26 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #23731 globally and #2590 in its home market, demonstrating a -0.28% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying MAAT PHARMA S.A. EO-1's stock price €7.00 by its total outstanding shares 18751521 (18.75 Million).
MAAT PHARMA S.A. EO-1 Market Cap History: 2021 to 2026
MAAT PHARMA S.A. EO-1's market capitalization history from 2021 to 2026. Data shows change from $256.00 Million to $134.74 Million (-13.03% CAGR).
MAAT PHARMA S.A. EO-1 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how MAAT PHARMA S.A. EO-1's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 4RD by Market Capitalization
Companies near MAAT PHARMA S.A. EO-1 in the global market cap rankings as of March 19, 2026.
Key companies related to MAAT PHARMA S.A. EO-1 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
MAAT PHARMA S.A. EO-1 Historical Marketcap From 2021 to 2026
Between 2021 and today, MAAT PHARMA S.A. EO-1's market cap moved from $256.00 Million to $ 134.74 Million, with a yearly change of -13.03%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €134.74 Million | +47.68% |
| 2025 | €91.24 Million | -43.57% |
| 2024 | €161.68 Million | +31.66% |
| 2023 | €122.80 Million | -19.44% |
| 2022 | €152.44 Million | -40.45% |
| 2021 | €256.00 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of MAAT PHARMA S.A. EO-1 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $134.74 Million USD |
| MoneyControl | $134.74 Million USD |
| MarketWatch | $134.74 Million USD |
| marketcap.company | $134.74 Million USD |
| Reuters | $134.74 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.